# Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma

> **NCT03761056** · PHASE2 · COMPLETED · sponsor: **Kite, A Gilead Company** · enrollment: 42 (actual)

## Conditions studied

- B-cell Lymphoma

## Interventions

- **BIOLOGICAL:** Axicabtagene Ciloleucel
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT03761056
- **Lead sponsor:** Kite, A Gilead Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-29
- **Primary completion:** 2023-10-12
- **Final completion:** 2023-10-12
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2024-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03761056

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03761056, "Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT03761056. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*